Renaissance Capital logo

CYT News

US IPO Weekly Recap: IPO market in full swing as biotechs lead a 16 IPO week

LYEL

The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL)...read more

Oncology biotech Cyteir Therapeutics prices IPO at $18 high end

Cyteir Therapeutics logo

Cyteir Therapeutics, an early stage oncology biotech developing small molecule therapies that inhibit DNA damage repair, raised $133 million by offering 7.4 million shares at $18, the high end of the range of $16 to $18. Cyteir Therapeutics' lead candidate, CYT...read more

Oncology biotech Cyteir Therapeutics sets terms for $126 million IPO

Cyteir Therapeutics logo

Cyteir Therapeutics, an early stage oncology biotech developing small molecule therapies that inhibit DNA damage repair, announced terms for its IPO on Monday. The Lexington, MA-based company plans to raise $126 million by offering 7.4 million shares at a...read more

US IPO Week Ahead: Biotechs and software lead a 15 IPO week

LYEL

Updated Monday, 6/14. 15 IPOs are currently slated to raise $2.5 billion in the week ahead, led by a preclinical biotech being valued at $4.7 billion. The largest deal of the week, Lyell Immunopharma (LYEL) plans to raise...read more